A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929.On page 1927, “Safety and tolerability assessments” section, third paragraph, first sentence should read from “Fifteen subjects exited the study due to AE...
Main Authors: | Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-01-01
|
Series: | Clinical Ophthalmology |
Online Access: | https://www.dovepress.com/corrigendum2-a-phase-iiiii-randomized-double-masked-vehicle-contr-peer-reviewed-article-OPTH |
Similar Items
-
A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
by: Tauber J, et al.
Published: (2018-12-01) -
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
by: Tauber J, et al.
Published: (2018-10-01) -
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
by: Sheppard J, et al.
Published: (2021-01-01) -
OTX1 and OTX2 as possible molecular markers of sinonasal carcinomas and olfactory neuroblastomas
by: Cristina Pirrone, et al.
Published: (2017-02-01) -
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
by: Paul Karpecki, et al.
Published: (2023-11-01)